查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1890428

全球吸入生物製劑市場評估：依生物製劑類型、應用、劑型/給藥裝置、通路、地區、機會與預測（2018-2032 年）

Global Inhalable Biologics Market Assessment, By Type of Biologic, By Application, By Dosage Form/Delivery Device, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F
出版日期: | 出版商: Markets & Data | 英文 252 Pages | 商品交期: 3-5個工作天內

價格

吸入生物製劑市場呈現強勁成長勢頭，預計到 2024 年將達到 35.5 億美元，到 2032 年將達到 103.5 億美元，複合年增長率 (CAGR) 為 14.30%。推動市場擴張的因素包括氣喘、慢性阻塞性肺病 (COPD) 和囊性纖維化等呼吸系統疾病的日益普遍，以及人口老化。對非侵入性給藥方式的需求不斷增長，進一步加速了其應用，提高了患者的便利性並改善了藥物療效。生物製劑製劑和吸入裝置技術的進步，正在推動更有效、更具標靶性的療法的開發。

患者和醫療保健專業人員對非侵入性給藥方式的偏好，正在顯著推動吸入生物製劑市場的成長。與傳統注射不同，吸入給藥途徑無痛、易用且標靶性強，因此對於需要頻繁給藥的慢性疾病尤其有利。吸入給藥可使藥物快速吸收並直接輸送至肺部，用於治療呼吸系統疾病。此外，吸入給藥還能減少全身暴露，進而減少副作用。這對於局部治療可改善預後的疾病（例如囊性纖維化、氣喘和肺部感染）尤其重要。吸入生物製劑還能消除注射帶來的不適和不便，進而提高病患的用藥遵從性。

例如，2024年1月，Insmed公司進一步推動了這一趨勢，宣布其非結核分枝桿菌治療藥物ARIKAYCE（阿米卡星脂質體吸入混懸液）的III期臨床試驗取得積極結果。該研究證實了ARIKAYCE對非結核分枝桿菌肺病的療效，並強調了吸入給藥在治療這種複雜疾病的臨床價值。該研究表明，與安慰劑相比，吸入生物製劑能顯著改善肺功能和細菌清除率，證明吸入生物製劑可以滿足呼吸護理方面未被滿足的需求，同時為注射提供了一種便捷的替代方案。因此，隨著更多生物製劑被重新設計為吸入劑型，這有望擴大患者用藥途徑，提高已開發市場和新興市場的依從性，從而推動市場持續成長。

目錄

第一章：專案範圍與定義

第二章：研究方法

第三章：摘要整理

第四章：2018-2032年全球吸入生物製品市場展望

  • 市場規模分析與預測
    • 依價值劃分
  • 市佔率分析與預測
    • 依生物製品類型劃分
      • 勝肽類和蛋白質類
      • 單株抗體類
      • 疫苗類
      • 其他類
    • 依應用領域
      • 呼吸系統疾病
      • 傳染病
      • 糖尿病
      • 其他
    • 依劑型/給藥裝置
      • 乾粉吸入器
      • 定量吸入器
      • 霧化器
      • 其他
    • 依分銷管道
      • 醫院藥房
      • 零售藥房
      • 線上藥房
    • 依地區
      • 北美
      • 歐洲
      • 亞太地區
      • 南美
      • 中東和非洲
    • 依公司劃分的市佔率分析
  • 2024年市場地圖分析
    • 依生物製品類型
    • 依應用領域
    • 依劑型及給藥裝置劃分
    • 依分銷管道劃分
    • 依地區劃分

第五章 北美吸入生物製品市場展望，2018-2032

  • 市場規模分析與預測
    • 依價值劃分
  • 市佔率分析與預測
    • 依生物製品類型劃分
      • 勝肽類和蛋白質類
      • 單株抗體類
      • 疫苗類
      • 其他類
    • 依應用領域劃分
      • 呼吸系統疾病類
      • 傳染病類
      • 糖尿病類
      • 其他類
    • 依劑型/給藥裝置劃分
      • 乾粉吸入器類
      • 定量吸入器
      • 霧化器
      • 其他
    • 依分銷管道劃分
      • 醫院藥房
      • 零售藥房
      • 網路藥房
    • 依國家/地區劃分的市場佔有率
      • 美國
      • 加拿大
      • 墨西哥
  • 依國家/地區劃分的市場評估
    • 美國吸入生物製品市場展望，2018-2032
      • 市場規模分析及預測
      • 市佔率分析及預測
    • 加拿大
    • 墨西哥

第六章：歐洲吸入生物製品市場展望，2018-2032

  • 德國
  • 法國
  • 義大利
  • 英國
  • 俄羅斯
  • 荷蘭
  • 西班牙
  • 土耳其
  • 波蘭

第七章：亞太地區吸入生物製品市場展望，2018-2032

  • 印度
  • 中國
  • 日本
  • 澳大利亞
  • 越南
  • 南亞韓國
  • 印尼
  • 菲律賓

第八章：南美洲吸入生物製品市場展望（2018-2032）

  • 巴西
  • 阿根廷

第九章：中東及非洲吸入生物製品市場展望（2018-2032）

  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第十章：供需分析

第十一章：價值鏈分析

第十二章：波特五力分析

第十三章：PESTLE分析

第十四章：定價分析

第十五章：市場動態

  • 市場驅動因素
  • 市場挑戰

第十六章：市場趨勢與發展

第十七章：監理架構

  • 臨床試驗
  • 監理核准

第十八章：專利格局

第十九章：個案研究

第二十章：競爭格局

  • 五大市場領導者的競爭矩陣
  • 五大公司的SWOT分析
  • 十大主要參與者公司
    • 艾伯維公司 (AbbVie Inc.)
      • 公司詳情
      • 關鍵管理人員
      • 產品與服務
      • 財務資訊（已公佈）
      • 主要市場趨勢與地理擴張
      • 近期發展/合作/夥伴關係/併購
    • 阿斯特捷利康 (AstraZeneca)
    • 諾華 (Novartis AG)
    • 勃林格殷格翰國際有限公司 (Boehringer Ingelheim International GmbH)
    • 凱西藥 (Chiesi Farmaceutici S.p.A.)
    • 康希諾生物 (CansinoBl0)
    • 輝瑞公司
    • 安進公司
    • 歐庫根公司
    • 英賽德公司

以上列出的公司排名不分先後，排名依據為市場佔有率，並可能根據研究過程中獲得的資訊進行調整。

第21章：策略建議

第22章：關於研究公司及免責聲明

Product Code: MX13879

Inhalable biologics market is experiencing robust growth, valued at 3.55 billion in 2024 and projected to reach 10.35 billion by 2032 at a CAGR of 14.30%. This market expansion is driven by the increasing prevalence of respiratory diseases such as asthma, COPD, and cystic fibrosis, as well as a growing elderly population. The rising demand for non-invasive drug delivery methods is further accelerating their adoption, offering patients enhanced convenience and improved drug efficacy. Advances in biologic formulations and inhaler device technology are enabling the development of more effective, targeted therapies.

The preference for non-invasive delivery methods among patients and healthcare providers is driving significant growth in the inhalable biologics market. Unlike traditional injectables, inhalation offers a painless, user-friendly, and targeted route of administration, making it particularly advantageous for chronic conditions that require frequent dosing. Inhalation enables rapid drug absorption, direct delivery to the lungs for respiratory diseases, and lower systemic exposure, reducing adverse effects. This is particularly important in diseases such as cystic fibrosis, asthma, and pulmonary infections, where localized treatment improves therapeutic outcomes. Inhalable biologics also enhance adherence, as they eliminate the discomfort and logistical barriers associated with injections.

For instance, in January 2024, Insmed Incorporated supported this trend and announced positive Phase 3 data for ARIKAYCE (amikacin liposome inhalation suspension), demonstrating its efficacy in treating non-tuberculous mycobacterial lung disease and underscoring the clinical value of inhaled delivery for complex conditions. The trial showed significant improvements in lung function and bacterial clearance compared to the placebo, reflecting how inhaling biologics can address unmet needs in respiratory care while offering a convenient alternative to injections. The market is therefore poised for sustained growth as more biological advances are reformulated for inhalation, enabling broader patient access and better compliance in both developed and emerging markets.

Rising Incidence of Respiratory and Infectious Diseases Fuels Demand

The increasing global burden of respiratory and infectious diseases remains a significant driver of the inhalable biologics market. Conditions like asthma, chronic obstructive pulmonary disease (COPD), tuberculosis, and post-COVID pulmonary complications are prevalent and require long-term management. Inhalable biologics offer a promising therapeutic avenue by delivering targeted, effective treatments directly to affected lung tissues, thereby minimizing systemic toxicity and improving efficacy.

According to the World Health Organization (WHO), asthma affected approximately 262 million people worldwide and caused over 455,000 deaths in 2023, underscoring the need for innovative therapies. Additionally, the ongoing challenge of antimicrobial resistance has highlighted the importance of novel delivery methods for treating lung infections.

Reflecting this demand, AstraZeneca PLC launched Tezspire (tezepelumab) in February 2023, a monoclonal antibody administered via inhalation for patients with severe, uncontrolled asthma. This milestone demonstrates how inhalable biologics can effectively control exacerbations and reduce hospitalizations, providing tangible benefits over standard therapies. As respiratory diseases remain among the top causes of morbidity globally, and infectious disease outbreaks continue to emerge, the role of inhalable biologics as frontline therapies will only expand, driving increased investment and market penetration across therapeutic areas.

Technological Advancements in Inhalation Devices Accelerate Market Growth

The success of inhalable biologics depends not only on drug formulation but also on the efficiency and precision of the delivery device. Over the past few years, significant advancements in inhalation devices, such as dry powder inhalers (DPIs), metered dose inhalers (MDIs), nebulizers, and smart digital devices, have enhanced the clinical performance and usability of inhalable therapies. These technologies are specifically designed to protect biologic molecules, ensure optimal deposition in targeted lung regions, and enable reproducible dosing even in patients with compromised respiratory function. Recent innovations include devices integrated with sensors, Bluetooth connectivity, and real-time feedback mechanisms to monitor patient adherence and inhalation technique.

For instance, in October 2023, Chiesi Farmaceutici S.p.A. launched a next-generation digitally connected DPI platform designed to improve adherence and personalize therapy for patients using inhaled biologics. The platform records inhalation parameters, provides reminders, and shares data with healthcare providers, helping to optimize treatment plans. Such advancements significantly improve patient outcomes, reduce healthcare costs associated with poor adherence, and expand the usability of inhalable biologics across diverse patient populations. The integration of innovative technology in delivery devices is transforming the market landscape, making inhalation a highly competitive alternative to traditional biologic administration routes.

Supportive Regulatory and Policy Environment Encourages Innovation

The regulatory and policy landscape has evolved to facilitate faster development, approval, and market entry of inhalable biologics, recognizing their potential in addressing critical healthcare challenges. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have introduced expedited pathways, guidance documents, and emergency authorizations for inhaled biologics, particularly in the wake of pandemics and the growing burden of chronic diseases. These measures reduce time-to-market, lower development risks, and provide clearer compliance pathways for innovators.

For instance, in May 2023, the U.S. FDA granted Emergency Use Authorization (EUA) for CanSino Biologics Inc.'s inhalable COVID-19 vaccine, Convidecia Air. This approval marked a milestone in vaccine innovation, demonstrating the feasibility and benefits of inhalable biologics for mass immunization programs. Regulatory support for such groundbreaking therapies encourages R&D investments, fosters public-private partnerships, and attracts new entrants to the market, creating a dynamic and competitive environment. The continued evolution of policies to accommodate novel biologic modalities ensures that inhalable therapies remain at the forefront of biopharmaceutical innovation, ultimately expanding treatment options and improving global health outcomes.

North America Dominates the Global Inhalable Biologics Market

North America holds a commanding position in the global inhalable biologics market, supported by its robust healthcare infrastructure, high research and development spending, and strong presence of leading biopharma companies. The U.S. is a particularly fertile ground for innovation, given its concentration of clinical research organizations, regulatory expertise, and early adoption of novel therapies. Companies like Pfizer Inc., Amgen Inc., and AbbVie Inc. have invested heavily in developing and commercializing inhalable biologics, capitalizing on the region's high burden of respiratory and chronic diseases.

For instance, in 2024, the Centers for Medicare & Medicaid Services (CMS) announced a 5% increase in reimbursement rates for inhalable biologics used in the management of chronic diseases, providing additional incentives for their adoption in clinical practice. This favorable reimbursement policy, coupled with growing physician awareness and patient demand for non-invasive therapies, has reinforced North America's leadership. The region also benefits from a supportive regulatory environment and advanced distribution networks, ensuring timely access to innovative treatments. As pipeline candidates advance to commercialization and new indications emerge, North America is expected to maintain its dominance, serving as the primary driver of global inhalable biologics market growth in the coming years.

Future Market Scenario: Personalized and Systemic Applications of Inhalable Biologics

The future of the inhalable biologics market is poised to evolve beyond respiratory diseases, with expanding applications in systemic and personalized medicine. Advances in nanoparticle formulations, carrier systems, and device engineering are enabling the development of inhalable therapies for oncology, diabetes, and rare genetic disorders. Personalized medicine is emerging as a key trend, where treatments are tailored to individual genetic profiles and delivered through smart inhalers equipped with artificial intelligence (AI) and data analytics capabilities.

According to a 2024 NIH report, inhalable insulin and GLP-1 receptor agonists for diabetes management are progressing into late-stage trials, signaling strong momentum toward broader applications. Furthermore, AI-driven adherence monitoring and real-world data integration will help optimize outcomes and refine treatment strategies. These innovations will expand the therapeutic reach of inhalable biologics, reduce healthcare costs by improving adherence and efficacy, and attract investments from both traditional pharma companies and digital health startups. As systemic and precision applications gain regulatory and clinical validation, the inhalable biologics market is expected to experience transformative growth, reshaping the future of biologic therapy delivery and broadening its impact across various therapeutic areas.

Key Players Landscape and Outlook

The global inhalable biologics market is characterized by intense competition, with leading players employing strategies such as mergers, acquisitions, partnerships, and technology licensing to strengthen their market positions.

For instance, in November 2023, Novartis AG announced a partnership with a U.S.-based device technology company to co-develop a smart dry powder inhaler for biologics targeting COPD and asthma, demonstrating the convergence of drug and device innovation.

Similarly, in December 2023, Boehringer Ingelheim International GmbH acquired a biologics-focused R&D firm to accelerate its inhalable biologics pipeline and expand its capabilities in advanced drug delivery systems.

These moves reflect a strategic focus on integrating cutting-edge delivery technologies, expanding therapeutic indications, and responding to increasing demand for patient-centric therapies. The competitive landscape is also characterized by heightened R&D investments, pipeline diversification, and collaborations with digital health companies to deliver personalized, data-driven solutions. Such strategic initiatives are expected to intensify market competition while improving access to innovative therapies and enhancing patient outcomes globally.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Inhalable Biologics Market Outlook, 2018-2032F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Type of Biologic
      • 4.2.1.1. Peptides & Proteins
      • 4.2.1.2. Monoclonal Antibodies
      • 4.2.1.3. Vaccines
      • 4.2.1.4. Others
    • 4.2.2. By Application
      • 4.2.2.1. Respiratory Diseases
      • 4.2.2.2. Infectious Diseases
      • 4.2.2.3. Diabetes
      • 4.2.2.4. Others
    • 4.2.3. By Dosage Form/Delivery Device
      • 4.2.3.1. Dry Powder Inhalers
      • 4.2.3.2. Metered Dose Inhalers
      • 4.2.3.3. Nebulizers
      • 4.2.3.4. Others
    • 4.2.4. By Distribution Channel
      • 4.2.4.1. Hospital Pharmacies
      • 4.2.4.2. Retail Pharmacies
      • 4.2.4.3. Online Pharmacies
    • 4.2.5. By Region
      • 4.2.5.1. North America
      • 4.2.5.2. Europe
      • 4.2.5.3. Asia-Pacific
      • 4.2.5.4. South America
      • 4.2.5.5. Middle East and Africa
    • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 4.3. Market Map Analysis, 2024
    • 4.3.1. By Type of Biologic
    • 4.3.2. By Application
    • 4.3.3. By Dosage Form/Delivery Device
    • 4.3.4. By Distribution Channel
    • 4.3.5. By Region

5. North America Inhalable Biologics Market Outlook, 2018-2032F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Type of Biologic
      • 5.2.1.1. Peptides & Proteins
      • 5.2.1.2. Monoclonal Antibodies
      • 5.2.1.3. Vaccines
      • 5.2.1.4. Others
    • 5.2.2. By Application
      • 5.2.2.1. Respiratory Diseases
      • 5.2.2.2. Infectious Diseases
      • 5.2.2.3. Diabetes
      • 5.2.2.4. Others
    • 5.2.3. By Dosage Form/Delivery Device
      • 5.2.3.1. Dry Powder Inhalers
      • 5.2.3.2. Metered Dose Inhalers
      • 5.2.3.3. Nebulizers
      • 5.2.3.4. Others
    • 5.2.4. By Distribution Channel
      • 5.2.4.1. Hospital Pharmacies
      • 5.2.4.2. Retail Pharmacies
      • 5.2.4.3. Online Pharmacies
    • 5.2.5. By Country Share
      • 5.2.5.1. United States
      • 5.2.5.2. Canada
      • 5.2.5.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Inhalable Biologics Market Outlook, 2018-2032F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Type of Biologic
          • 5.3.1.2.1.1. Peptides & Proteins
          • 5.3.1.2.1.2. Monoclonal Antibodies
          • 5.3.1.2.1.3. Vaccines
          • 5.3.1.2.1.4. Others
        • 5.3.1.2.2. By Application
          • 5.3.1.2.2.1. Respiratory Diseases
          • 5.3.1.2.2.2. Infectious Diseases
          • 5.3.1.2.2.3. Diabetes
          • 5.3.1.2.2.4. Others
        • 5.3.1.2.3. By Dosage Form/Delivery Device
          • 5.3.1.2.3.1. Dry Powder Inhalers
          • 5.3.1.2.3.2. Metered Dose Inhalers
          • 5.3.1.2.3.3. Nebulizers
          • 5.3.1.2.3.4. Others
        • 5.3.1.2.4. By Distribution Channel
          • 5.3.1.2.4.1. Hospital Pharmacies
          • 5.3.1.2.4.2. Retail Pharmacies
          • 5.3.1.2.4.3. Online Pharmacies
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Inhalable Biologics Market Outlook, 2018-2032F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Turkey
  • 6.9. Poland

7. Asia-Pacific Inhalable Biologics Market Outlook, 2018-2032F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Inhalable Biologics Market Outlook, 2018-2032F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Inhalable Biologics Market Outlook, 2018-2032F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

  • 15.1. Market Drivers
  • 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework

  • 17.1. Clinical Trials
  • 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

  • 20.1. Competition Matrix of Top 5 Market Leaders
  • 20.2. SWOT Analysis for Top 5 Players
  • 20.3. Key Players Landscape for Top 10 Market Players
    • 20.3.1. AbbVie Inc.
      • 20.3.1.1. Company Details
      • 20.3.1.2. Key Management Personnel
      • 20.3.1.3. Products and Services
      • 20.3.1.4. Financials (As Reported)
      • 20.3.1.5. Key Market Focus and Geographical Presence
      • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 20.3.2. AstraZeneca
    • 20.3.3. Novartis AG
    • 20.3.4. Boehringer Ingelheim International GmbH
    • 20.3.5. Chiesi Farmaceutici S.p.A.
    • 20.3.6. CansinoBl0.
    • 20.3.7. Pfizer Inc.
    • 20.3.8. Amgen Inc.
    • 20.3.9. Ocugen, Inc.
    • 20.3.10. Insmed Incorporated

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 2. Global Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 3. Global Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 4. Global Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 5. Global Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 6. Global Inhalable Biologics Market Share (%), By Region, 2018-2032F
  • Figure 7. North America Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 8. North America Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 9. North America Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 10. North America Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 11. North America Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 12. North America Inhalable Biologics Market Share (%), By Country, 2018-2032F
  • Figure 13. United States Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 14. United States Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 15. United States Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 16. United States Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 17. United States Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 18. Canada Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 19. Canada Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 20. Canada Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 21. Canada Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 22. Canada Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 23. Mexico Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 24. Mexico Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 25. Mexico Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 26. Mexico Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 27. Mexico Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 28. Europe Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 29. Europe Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 30. Europe Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 31. Europe Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 32. Europe Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 33. Europe Inhalable Biologics Market Share (%), By Country, 2018-2032F
  • Figure 34. Germany Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 35. Germany Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 36. Germany Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 37. Germany Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 38. Germany Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 39. France Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 40. France Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 41. France Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 42. France Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 43. France Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 44. Italy Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 45. Italy Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 46. Italy Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 47. Italy Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 48. Italy Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 49. United Kingdom Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 50. United Kingdom Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 51. United Kingdom Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 52. United Kingdom Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 53. United Kingdom Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 54. Russia Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 55. Russia Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 56. Russia Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 57. Russia Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 58. Russia Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 59. Netherlands Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 60. Netherlands Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 61. Netherlands Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 62. Netherlands Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 63. Netherlands Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 64. Spain Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 65. Spain Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 66. Spain Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 67. Spain Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 68. Spain Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 69. Turkey Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 70. Turkey Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 71. Turkey Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 72. Turkey Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 73. Turkey Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 74. Poland Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 75. Poland Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 76. Poland Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 77. Poland Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 78. Poland Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 79. Asia-Pacific Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 80. Asia-Pacific Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 81. Asia-Pacific Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 82. Asia-Pacific Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 83. Asia-Pacific Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 84. Asia-Pacific Inhalable Biologics Market Share (%), By Country, 2018-2032F
  • Figure 85. India Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 86. India Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 87. India Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 88. India Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 89. India Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 90. China Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 91. China Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 92. China Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 93. China Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 94. China Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 95. Japan Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 96. Japan Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 97. Japan Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 98. Japan Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 99. Japan Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 100. Australia Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 101. Australia Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 102. Australia Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 103. Australia Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 104. Australia Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 105. Vietnam Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 106. Vietnam Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 107. Vietnam Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 108. Vietnam Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 109. Vietnam Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 110. South Korea Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 111. South Korea Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 112. South Korea Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 113. South Korea Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 114. South Korea Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 115. Indonesia Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 116. Indonesia Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 117. Indonesia Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 118. Indonesia Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 119. Indonesia Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 120. Philippines Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 121. Philippines Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 122. Philippines Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 123. Philippines Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 124. Philippines Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 125. South America Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 126. South America Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 127. South America Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 128. South America Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 129. South America Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 130. South America Inhalable Biologics Market Share (%), By Country, 2018-2032F
  • Figure 131. Brazil Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 132. Brazil Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 133. Brazil Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 134. Brazil Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 135. Brazil Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 136. Argentina Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 137. Argentina Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 138. Argentina Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 139. Argentina Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 140. Argentina Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 141. Middle East & Africa Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 142. Middle East & Africa Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 143. Middle East & Africa Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 144. Middle East & Africa Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 145. Middle East & Africa Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 146. Middle East & Africa Inhalable Biologics Market Share (%), By Country, 2018-2032F
  • Figure 147. Saudi Arabia Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 148. Saudi Arabia Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 149. Saudi Arabia Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 150. Saudi Arabia Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 151. Saudi Arabia Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 152. UAE Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 153. UAE Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 154. UAE Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 155. UAE Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 156. UAE Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 157. South Africa Inhalable Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 158. South Africa Inhalable Biologics Market Share (%), By Type of Biologic, 2018-2032F
  • Figure 159. South Africa Inhalable Biologics Market Share (%), By Application, 2018-2032F
  • Figure 160. South Africa Inhalable Biologics Market Share (%), By Dosage Form / Delivery Device, 2018-2032F
  • Figure 161. South Africa Inhalable Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 162. By Type of Biologic Map - Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 163. By Application Map - Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 164. By Dosage Form / Delivery Device Map - Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 165. By Distribution Channel Map - Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 166. By Region Map - Market Size (USD Billion) & Growth Rate (%), 2024